This site includes reports of thrombotic microangiopathy in people
taking emicizumab-kxwh whether or not emicizumab-kxwh caused the
While consumers and healthcare professionals are encouraged to report adverse events in the post-marketing setting, the event in these reports may have been related to the underlying disease being treated, or caused by some other drug being taken concurrently, or occurred for other reasons not associated with emicizumab-kxwh. The inclusion of thrombotic microangiopathy events within this site is not an admission that emicizumab-kxwh caused or contributed the event.
The information in these reports cannot be used to establish the event rates over time, or compare event rates between drug products. In addition, the number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of the events associated with emicizumab-kxwh.
While reports made in the post-marketing setting are a valuable source of information, they have limitations, including that they may include incomplete, inaccurate, untimely, unverified information. As a result, information on this site does not confirm or establish, or represent an admission that a causal relationship between emicizumab-kxwh and the reported adverse event exists.